Bioverativ Inc (NASDAQ:BIVV) – Equities research analysts at William Blair upped their FY2017 earnings estimates for shares of Bioverativ in a report issued on Wednesday, according to Zacks Investment Research. William Blair analyst R. Prasad now forecasts that the biotechnology company will post earnings of $2.65 per share for the year, up from their previous estimate of $2.51. William Blair also issued estimates for Bioverativ’s Q4 2017 earnings at $0.68 EPS and FY2018 earnings at $3.92 EPS.
A number of other analysts have also weighed in on BIVV. Zacks Investment Research raised Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 price objective on the stock in a research report on Thursday, October 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $71.00 price objective on shares of Bioverativ in a research report on Monday, October 23rd. Deutsche Bank set a $53.00 price objective on Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Jefferies Group boosted their target price on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research note on Thursday, January 18th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $65.00 target price on shares of Bioverativ in a research note on Thursday, January 18th. Thirteen research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Bioverativ has an average rating of “Hold” and an average target price of $62.86.
Bioverativ (NASDAQ BIVV) traded down $0.49 during trading on Friday, hitting $103.50. The stock had a trading volume of 3,091,397 shares, compared to its average volume of 3,335,938. Bioverativ has a 1-year low of $41.88 and a 1-year high of $104.30. The stock has a market capitalization of $11,230.00 and a price-to-earnings ratio of 25.31.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Robeco Institutional Asset Management B.V. acquired a new position in Bioverativ in the fourth quarter valued at $105,000. American Assets Investment Management LLC acquired a new position in Bioverativ in the fourth quarter valued at $108,000. Advisors Asset Management Inc. acquired a new position in Bioverativ in the third quarter valued at $137,000. TCI Wealth Advisors Inc. acquired a new position in Bioverativ in the third quarter valued at $186,000. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new position in Bioverativ in the third quarter valued at $190,000. Institutional investors own 95.14% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/05/william-blair-comments-on-bioverativ-incs-fy2017-earnings-bivv.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Get a free copy of the Zacks research report on Bioverativ (BIVV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.